ClinicalTrials.gg
RecruitingNCT05265299Updated Mar 16, 2026

Trial to Determine Effective Aspirin Dose in COPD

A Phase 3 interventional study of Aspirin 81mg and Aspirin 162 mg in Pulmonary Disease, Chronic Obstructive, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Johns Hopkins University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Pulmonary Disease, Chronic Obstructive by Johns Hopkins University — 4 open to participants now, 4 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Johns Hopkins University.

Planned enrollment
14th of 19
48 · median 89
Started
2023
the only one that year
Phase 3
2 of 23
1 open now
Registered
20th of 23
by date

Among the 23 studies in Pulmonary Disease, Chronic Obstructive by Johns Hopkins University, this one is the 14th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 3, and was the 20th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

4 of the 23 studies in Pulmonary Disease, Chronic Obstructive by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Pulmonary Disease, Chronic Obstructive by Johns Hopkins University, or all of them as a file.
02

Study summary

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States. Current treatments for COPD focus on inhaler therapies that do not address manifestations of the disease on other organ systems. Platelets, which are small blood cells that typically help with clotting, are also involved in generalized inflammation and dysfunctionality of immune cells when these cells become activated. Activated platelets have long been known to play a role in the development of cardiovascular disease. However, there is recent evidence that activated platelets may be involved in worse respiratory symptoms in COPD independent of cardiovascular disease. Individuals with COPD who are taking aspirin, which is an antiplatelet agent that blocks activation of platelets, have been shown to have improved respiratory symptoms, fewer COPD flares, and lower mortality. The investigators' ultimate goal is to study whether aspirin use improves respiratory symptoms independent of cardiovascular disease. The investigators are conducting the current pilot trial to determine the optimal dose of aspirin that blocks platelet activation in this population and investigate whether there are any blood or urine tests that can help with understanding response to therapy. The results will inform the design of a larger trial investigating clinical outcomes. The investigators hypothesize that daily low-dose aspirin will not be sufficient to adequately suppress platelet activation and that an aspirin dose of at least 162mg daily will be necessary.

Read the detailed description

The trial will enroll individuals with chronic obstructive pulmonary disease (COPD). The primary design will be a randomized double-blind 6-sequence, 3-period, 3-treatment sequential crossover trial for which the investigators will randomize participants to receive 81mg, 162mg, and 325mg aspirin in one of six pre-specified sequences with a 14-day washout period between doses. Participants will have three follow-up visits after randomization.

Individuals who agree to participate in the clinical trial will be randomized to one of six treatment sequences using a computer algorithm at the baseline study visit. Study drug will be provided by the Johns Hopkins Research Pharmacy and participants instructed to take one pill once per day at the same time. All study drug doses will be compounded to appear identical and placed in identical containers fitted with an electronic cap for monitoring medication adherence. Participants will be scheduled to return for a follow-up visit at two weeks, six weeks, and ten weeks after randomization. Blood and urine samples will be collected at each visit. Data will be collected by the principal investigator or trained study coordinator and will be electronically entered into a database stored on the secure Johns Hopkins servers through an online interface that is password protected. Urine will be collected and analyzed for 11-dehydro-thromboxane B2 at each study visit and constitutes the primary outcome of the study. Secondary outcomes will include measurement of platelet reactivity to U46619, a thromboxane A2 agonist, through identification of platelet surface markers CD62P, CD63, CD154 and PAC1.

The following adherence measurements will also be collected:

  1. Drug discontinuation rate
  2. Date and time of each dose of study medication obtained through electronic monitoring to assess adherence

The following clinical data will be collected at randomization:

1. Spirometry performed before and after administration of albuterol per American Thoracic Society protocol in a certified laboratory

The following clinical data will be collected at randomization and each subsequent study visit:

  1. Respiratory symptom and quality of life questionnaires
  2. Occurrence of COPD flares (exacerbations)
03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥40 years
  • Former smoker
  • At least 10 pack-year smoking history
  • Post-bronchodilator ratio of to forced vital capacity (FEV1/FVC) \< 0.7

Exclusion criteria

Exclusion Criteria:

  • History of myocardial infarction, percutaneous coronary intervention, or stroke
  • Currently taking antiplatelet therapy (other than aspirin 81mg) or anticoagulant medication
  • to aspirin (including low count, hematocrit \<25%, known aspirin-exacerbated respiratory disease, bleeding disorder, history of bleeding or gastrointestinal (GI) ulcer, coagulopathy, or major surgery within 6 weeks before randomization)
  • Oral within the past 6 weeks
  • Currently taking medication
  • Active (other than non-melanoma skin cancer)
  • Uncontrolled hypertension
  • Pregnant or planning pregnancy in the next year
  • Plans to move residence away from the immediate area within the next 3 months
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Sequence 1

    * Week 1-2: aspirin 81mg * Week 5-6: aspirin 162mg * Week 9-10: aspirin 325mg

    Drug: Aspirin 81mg · Drug: Aspirin 162 mg · Drug: Aspirin 325mg

  • Experimental
    Sequence 2

    * Week 1-2: aspirin 162mg * Week 5-6: aspirin 81mg * Week 9-10: aspirin 325mg

    Drug: Aspirin 81mg · Drug: Aspirin 162 mg · Drug: Aspirin 325mg

  • Experimental
    Sequence 3

    * Week 1-2: aspirin 325mg * Week 5-6: aspirin 81mg * Week 9-10: aspirin 162mg

    Drug: Aspirin 81mg · Drug: Aspirin 162 mg · Drug: Aspirin 325mg

  • Experimental
    Sequence 4

    * Week 1-2: aspirin 325mg * Week 5-6: aspirin 162mg * Week 9-10: aspirin 81mg

    Drug: Aspirin 81mg · Drug: Aspirin 162 mg · Drug: Aspirin 325mg

  • Experimental
    Sequence 5

    * Week 1-2: aspirin 162mg * Week 5-6: aspirin 325mg * Week 9-10: aspirin 81mg

    Drug: Aspirin 81mg · Drug: Aspirin 162 mg · Drug: Aspirin 325mg

  • Experimental
    Sequence 6

    * Week 1-2: aspirin 81mg * Week 5-6: aspirin 325mg * Week 9-10: aspirin 162mg

    Drug: Aspirin 81mg · Drug: Aspirin 162 mg · Drug: Aspirin 325mg

Interventions

06

What researchers measure

Primary outcomes

  1. Change in urinary 11-dehydro-thromboxane B2 level

    Urine 11-dehydro-thromboxane B2 level (pg/mg Creatinine) - a urinary metabolite of thromboxane A2.

    Time frame: Baseline, week 2, week 6, week 10

  2. Change in serum thromboxane B2 level

    Serum thromboxane B2

    Time frame: Baseline, week 2, week 6, week 10

Secondary outcomes

  1. Change in proportion of platelets displaying CD62P

    Proportion of platelets displaying CD62P (activated platelets) following stimulation with U46619, a thromboxane A2 agonist.

    Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks

  2. Change in proportion of platelets displaying CD63

    Proportion of platelets displaying CD63 (activated platelets) following stimulation with U46619, a thromboxane A2 agonist.

    Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks

  3. Change in proportion of platelets displaying CD154

    Proportion of platelets displaying CD154 (activated platelets) following stimulation with U46619, a thromboxane A2 agonist

    Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks

  4. Change in proportion of platelets displaying PAC1

    Proportion of platelets displaying PAC1 (activated platelets) following stimulation with U46619, a thromboxane A2 agonist

    Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.

Of 33 non-industry phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 56. This study's planned 43 months is close to that.

Counting every sponsor, half of 142 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2022
First posted
Mar 3, 2022
StartActual
May 16, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05265299
Responsible party
Sponsor
First posted
Mar 3, 2022
Start date
May 16, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 16, 2026

Study contacts

Wendy Lorizio, MD, MPH
Contact
wlorizi1@jhmi.edu
410-510-2449
Ashraf Fawzy, MD, MPH
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion